Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease
复制标题
DOI：
10.1007/s11010-005-9047-9
复制
发表时间：
2006-03-01
影响因子：
4.3
通讯作者：
Kimura, Kenjiro
中科院分区：
文献类型：
--
作者：
Kamijo, Atsuko;Sugaya, Takeshi;Kimura, Kenjiro
背景：我们报道尿L-FABP可反映慢性肾脏病（CKD）的进展。本研究旨在评价尿肝型脂肪酸结合蛋白（L-FABP）作为慢性肾脏病（CKD）监测生物标志物的临床意义。方法：使用人L-FABP ELISA试剂盒（CMIC.Co.，有限公司、日本东京）。对48例非糖尿病CKD患者进行为期一年的尿L-FABP与临床指标的相关性研究。为探讨肝源性血清L-FABP对尿L-FABP的影响，对73例慢性肾脏病（CKD）患者同时进行血、尿L-FABP测定。结果：尿L-FABP监测CKD的临界值为17.4 μ g/g.cr。使用受试者工作特征（ROC）曲线。尿L-FABP“高”组（n = 36）肾功能恶化程度明显高于尿L-FABP“低”组（n = 12）。肌酐清除率的降低伴随着尿L-FABP的增加，但不伴随尿蛋白的增加。CKD患者血L-FABP与尿L-FABP无相关性。结论：随着肾功能的恶化，尿中L-FABP排泄量增加。血清L-FABP对尿L-FABP无影响。尿L-FABP可能是监测CKD的一个有用的临床生物标志物。
Background: We reported that urinary L-FABP reflected the progression of chronic kidney disease (CKD). This study is aimed to evaluate the clinical significance of urinary liver type fatty acid binding protein (L-FABP) as a biomarker for monitoring CKD. Methods: Urinary L-FABP was measured using human L-FABP ELISA kit (CMIC.Co., Ltd., Tokyo, Japan). The relations between urinary L-FABP and clinical parameters were evaluated in non-diabetic CKD (n = 48) for a year. In order to evaluate the influence of serum L-FABP derived from liver upon urinary L-FABP, both serum and urinary L-FABP were simultaneously measured in patients with CKD (n = 73). Results: For monitoring CKD, the cut-off value in urinary L-FABP was determined as 17.4 mu g/g.cr. by using a receiver operating characteristics (ROC) curve. Renal function deteriorated significantly more in patients with 'high' urinary L-FABP (n = 36) than in those with 'low' L-FABP (n = 12). The decrease in creatinine clearance was accompanied by an increase in urinary L-FABP, but not in urinary protein. Serum L-FABP in patients with CKD was not correlated with urinary L-FABP. Conclusion: Urinary excretion of L-FABP increases with the deterioration of renal function. Serum L-FABP did not influence on urinary L-FABP. Urinary L-FABP may be a useful clinical biomarker for monitoring CKD.